Day One Biopharmaceuticals Is Being Bought for $2.5 Billion. Its Stock Is Jumping.

Day One Biopharmaceuticals’ stock surged on Friday after French drugmaker Servier announced an all-cash acquisition of the company for $21.50 per share. The deal values Day One Biopharmaceuticals, which specializes in pediatric cancer treatments, at $2.5 billion.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin